COMPASS Pathways is racing to bring a psilocybin-based treatment into late-stage testing, and the near-term story hinges on whether those results hold up and regulators stay supportive. The upside is a ready network of mental health clinics that could adopt it, but slow rollout, strict oversight, and the need for more funding could all curb how quickly the business scales.Read more
A mental health biotech is trying to bring a guided psilocybin treatment to people who haven’t responded to existing depression therapies, and a key late-stage study milestone could speed up the road to a first launch. The upside hinges on regulators staying supportive and clinics being ready to deliver the therapy, but delays, safety concerns, or extra fundraising could quickly change the picture.Read more
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
